The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Performance of a tumor-informed molecular residual disease (MRD) assay in resected bladder cancer with mixed or pure variant histology: Analysis of a real-world multicenter cohort.
 
Ajitha Kommalapati
No Relationships to Disclose
 
George Laliotis
Employment - Natera; Sirius Therapeutics, Inc.
Stock and Other Ownership Interests - Docus ai.; Natera; Sirius Therapeutics, Inc.
Consulting or Advisory Role - Docus ai.; Tegus
Travel, Accommodations, Expenses - Natera
 
Jordan Rich
No Relationships to Disclose
 
Shivaram Cumarasamy
No Relationships to Disclose
 
Samuel Rivero
No Relationships to Disclose
 
Shruti Sharma
No Relationships to Disclose
 
Charuta C Palsuledesai
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Meenakshi Malhotra
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Abbvie; Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Adam ElNaggar
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Minetta C. Liu
Employment - Natera
Stock and Other Ownership Interests - Natera
Research Funding - Eisai (Inst); Exact Sciences (Inst); Genomic Health (Inst); GRAIL (Inst); Menarini Silicon Biosystems (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Genomic Health; GRAIL; Menarini Silicon Biosystems; Merck; Natera; Pfizer
 
John P. Sfakianos
Consulting or Advisory Role - Asieris Pharmaceuticals; Merck; pacific edge; pacific edge
Speakers' Bureau - Natera
 
Charles Peyton
No Relationships to Disclose
 
James Ferguson
No Relationships to Disclose
 
Arnab Basu
Honoraria - Cardinal Health; Eisai; Gilead Sciences; Natera
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; EMD Serono; Seagen
Speakers' Bureau - Eisai
Research Funding - Astellas Pharma (Inst); AVEO (Inst); Bristol-Myers Squibb/Celgene (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Merck (Inst); Natera (Inst)